3rd GLP-1-Based Therapeutics Summit 2026

Welcome to the 3rd GLP-1 Based Therapeutics Summit - the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications.

Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection, promising unparalleled potential to conquer widespread chronic diseases.

The 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year, we're diving deep into the game-changing potential of multi-agonist combinations, next-generation tolerability, and strategic commercial planning.

Hear from the titans of the pharmaceutical industry, including Eli Lilly, AstraZeneca, Merck, and Takeda, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives.


URLs:
Website: https://go.evvnt.com/3369316-0?pid=2874
Brochure: https://go.evvnt.com/3369316-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals


Prices:
Drug Developer - Conference + Workshop Day: USD 4397.00,
Academic - Conference + Workshop Day: USD 3797.00,
Solution Provider - Conference + Workshop Day: USD 5397.00,
Drug Developer - Conference Only: USD 3099.00,
Academic - Conference Only: USD 2699.00,
Solution Provider - Conference Only: USD 3899.00



Speakers: Alok Pachori, Medical Director, Global Development, AstraZeneca, Kristin Fiorino, Medical Director, AstraZeneca, Fady Botros, Associate Vice President, Cardiometabolic Health Clinical Research Design, Eli Lilly, Belle Van Rosmalen, Director, Medical Development, Eli Lilly, Maria Trujillo, Senior Director, Quantitative Pharmacology and Pharmacometrics, Merck, Allison Goldfine, Executive Director, Translational Medicine, Cardiovascular and Metabolism, Novartis BioMedical Research, Rosemarie Sellati, Senior Director, Global Patient Advocacy, Regeneron, Adriana Ramos, Principal Scientist and Head of Lab, Sanofi, Bryan Jones, Chief Operating Officer, Aardvark Therapeutics, Steffen-Sebastian Bolz, Co-Founder, Executive Board Member and Chief Scientific Officer, Aphaia Pharma, Dr. Raj Reddy, President and Chief Executive Officer, Canary Global, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, Saleha Patel, Head of Pipeline and Commercialisation Strategy, Constructive Bio, Lin Quek, Associate Director, Gene Therapy Research, Fractyl Health, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Eduardo Martins, Chief Medical Officer, Sagimet Biosciences, Punit Dhillon, Chief Executive Officer and Director, Skye Biosciences, Steven Dickman, Founder and Chief Executive Officer, CBT Advisors, Marco Falasca, Professor, Metabolic Signalling, Department of Medicine and Surgery, Curtin University, Melissa Jones, Program Manager, Metabolic Disorders, FNIH, Niharika Samala, Associate Professor, Indiana University School of Medicine, Lawrence J Olson, Biotechnology Equity Research Analyst, Oppenheimer and Co., Krishna Kumar, Robinson Professor of Chemistry, Tufts University, Winston Dunn, Associate Professor, University of Kansas, Medical Center, Ashwani Singal, Professor of Medicine, University of Louisville